Evidence map›Paper›PMID 39881028›Full record

ArticleNature biotechnology2025

AAV vectors tested in perfused human livers.

Roland W Herzog, Ype P de Jong

Abstract read
PubMed Publisher
In one paragraph

Article in Nature biotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Gene therapy for hemophilia - From basic science to first approvals of "one-and-done" therapies.Molecular therapy : the journal of the American Society of Gene Therapy · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Roland W HerzogDepartment of Pediatrics, Herman B Wells Center for Pediatric Research, Indiana University, Indianapolis, IN, USA. rwherzog@iu.edu.ORCID http://orcid.org/0000-0002-7213-998X
Ype P de JongDivision of Gastroenterology & Hepatology, Weill Cornell Medicine, New York, NY, USA.ORCID http://orcid.org/0000-0001-6357-2370

Funding

Toward Safer Gene Therapy for Hemophilia AP01HL160472 · NHLBI · INDIANA UNIVERSITY INDIANAPOLIS · PI Roland W. Herzog · 2022 to 2026
$15.1M
Enhancing immune regulation in gene therapy for hemophiliaR01HL131093 · NHLBI · UNIVERSITY OF FLORIDA · PI Ype Peter De Jong, Roland W. Herzog · 2016 to 2026
$7.2M
Capsid- and genome-modified AAV3 vectors for hemophilia gene therapy.R01HL177230 · NHLBI · UNIVERSITY OF FLORIDA · PI Roland W. Herzog, Arun Srivastava · 2025 to 2026
$1.4M
NHLBI NIH HHS P01 HL160472NHLBI NIH HHS R01 HL131093NHLBI NIH HHS R01 HL177230
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.